Immunotherapy Combo Reduces Risk of Cancer Recurrence in Early-Stage Liver Cancer
The IMbrave050 study included 662 patients with HCC at high risk for recurrence after surgical resection or ablation with curative intent.
Diagnosis & Disease Information
Idacio, a Citrate-Free Biosimilar to Humira, Gets FDA Approval
The approval for Idacio was based on a review of data that showed similar pharmacokinetics, efficacy, safety, and immunogenicity to the reference adalimumab product.
Stereotactic Ablative Body Radiotherapy “Quite Safe” for Treating Oligometastases
Investigators characterized the toxicity of stereotactic body radiotherapy for oligometastases from predominantly prostate, colorectal, breast, and lung cancer.
Lytgobi Gets Accelerated Approval for Intrahepatic Cholangiocarcinoma
The approval was based on data from the open-label, single-arm phase 2b TAS-120-101 trial.
Bevacizumab Biosimilar Vegzelma Gets FDA Approval
Vegzelma is a vascular endothelial growth factor inhibitor.
Imfinzi Plus Chemotherapy Approved for Advanced Biliary Tract Cancer
The approval was based on data from the phase 3 TOPAZ-1 trial.
Pembrolizumab Combos Miss Primary Endpoints in Liver, Prostate Cancer Trials
The LEAP-002 study evaluated pembrolizumab plus lenvatinib in patients with uHCC; the KEYNOTE-921 study evaluated pembrolizumab plus docetaxel in patients with mCRPC.
AbbVie Seeks Crohn Disease Indication for Upadacitinib
The application is supported by data from the two phase 3 induction studies, U-EXCEED and U-EXCEL, and one phase 3 maintenance study, U-ENDURE.
Skyrizi Approved for Moderately to Severely Active Crohn Disease
The approval was based on data from two phase 3 induction studies, and one phase 3 maintenance study.
Oral STAT3 Inhibitor Granted Orphan Drug Status for Hepatocellular Carcinoma
Direct inhibition of STAT3 signaling by TTI-101 is expected to lead to reduced tumor growth.
- Loading...
Loading...
Next post in Oncology
Loading... 
Loading...